Johnson & Johnson axes late-stage program for depression therapy

Johnson & Johnson (NYSE:JNJ) has decided to discontinue a Phase 3 program for its depression therapy aticaprant due to insufficient efficacy, the pharma giant announced.

Known as VENTURA, the multi-center program comprised placebo-controlled trials designed to evaluate aticaprant as an adjunctive